Samuel Gillespie
Family Medicine · Moulton, ALNPI 1184612095
Payments from drug & device makers
Across 433 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$4K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$850
- Lilly USA, LLC$612
- AstraZeneca$362
- Bayer$316
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$3,82535%
- Food & beverage$6,96665%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,791 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 496 | $584,259 |
| JardianceEmpagliflozin | 227 | $200,603 |
| AuvelityDextromethorphan Hbr/Bupropion | 119 | $140,595 |
| TrulicityDulaglutide | 101 | $111,560 |
| EliquisApixaban | 108 | $106,601 |
| FarxigaDapagliflozin Propanediol | 129 | $104,839 |
| RexultiBrexpiprazole | 44 | $92,852 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 239 | $75,002 |
| OzempicSemaglutide | 59 | $62,954 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $56,693 |
| LinzessLinaclotide | 74 | $53,477 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $45,042 |
| VraylarCariprazine Hcl | 23 | $33,922 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $29,514 |
| XareltoRivaroxaban | 37 | $28,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $612 | $695,818597 claims |
| Boehringer IngelheimJardiance | $119 | $200,603227 claims |
| Axsome Therapeutics, Inc.Auvelity | $4,031 | $140,595119 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $362 | $127,358158 claims |
| PfizerEliquis | $230 | $106,601108 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $850 | $92,85244 claims |
| AbbVieLinzess, Vraylar | $1,116 | $87,39997 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $42 | $78,352155 claims |
| Novo NordiskOzempic | $210 | $62,95459 claims |
| Indivior Inc.Sublocade, Suboxone | $282 | $45,35145 claims |
| Johnson & JohnsonXarelto | $62 | $28,10337 claims |
| MerckJanuvia | $57 | $25,21423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Moulton
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.